Dopamine metabolism increases in post-mortem schizophrenic basal ganglia
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The dopamine-rich regions of post-mortem brains from 6 schizophrenics and 7 controls were analyzed. There were no significant changes in dopamine concentrations in basal ganglia and nucleus accumbens of schizophrenics compared with controls. Schizophrenic basal ganglia (putamen and caudate) showed significantly higher levels of homovanillic acid, and tyrosine hydroxylase activity. Among the schizophrenic patients, markedly high activity of tyrosine hydroxylase was measured in a patient diagnosed as catatonic type. He had not taken antipsychotic drugs for 3 months prior to death. In his relatives, three other schizophrenics were found to the second degree. A remarkable low level of dopamine and a high level of homovanillic acid measured indicate this case would have had an increased turnover rate of dopamine in the dopaminergic nerve terminals. Among the schizophrenic patients, there might be one group whose enzyme activity of dopamine synthesis in the brain is exceptionally high.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ectopic production of TH and a subsequent increase in catecholamine synthesis agrees with findings from valproic-acid based models of ASD33 and postmortem studies of patients with schizophrenia34.”
From Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome (2011) · cites this paper as [33]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331 · cited 1×
“Proteins were measured by the method of Lowry et al. (1951). Samples from both groups were assayed in parallel.”
MethodINCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA
Owen, F., Crow, T. J., Poulter, M., Cross, A. J., Longden, A., & Riley, G. J. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91740-3 · Cited by 518
Receptors for neurotransmitters and peptide hormones.
Pepeu, G., Kuhar, M. J., & Enna, S. J. (1980) · PubMed · Cited by 376
Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains
LEE, T., SEEMAN, P., TOURTELLOTTE, W. W., FARLEY, I. J., & HORNYKEIWICZ, O. (1978) · Nature · doi:10.1038/274897a0 · Cited by 351
Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography
Nagatsu, T., Oka, K., & Kato, T. (1979) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)81411-5 · Cited by 235 · cited 2×
“100 mM of fl-mercaptoethanol, l mM of ferrous ammonium sulphate, 4,000 units of catalase and sucrose homogenates without centrifugation were used (Nagatsu et al., 1978).”
MethodResultAdolfsson, R., Gottfries, C. G., Roos, B. E., & Winblad, B. (1979) · Journal of Neural Transmission · doi:10.1007/bf01250085 · Cited by 219
Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings
Crow, T. J., Baker, H. F., Cross, A. J., Joseph, M. H., Lofthouse, R., Longden, A., Owen, F., Riley, G. J., Glover, V., & Killpack, W. S. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.3.249 · Cited by 213
Bacopoulos, N. C., Spokes, E. G., Bird, E. D., & Roth, R. H. (1979) · Science · doi:10.1126/science.38504 · Cited by 102 · cited 3×
“Crow et aL (1979), Bacopoulos et al. (1979), Winblad et aL (1979) and Farley et aL (1980) reported no change in HVA concentration in the basal ganglia of schizophrenia. A significantly increased level of HVA in the putamen was reported only by Bird et aL (1979) in their 19 schizophrenic brains.”
BackgroundMethodInfluentialAberrant Monoamine Metabolite Levels in CSF and Family History of Schizophrenia
Sedvall, G. C. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780230031004 · Cited by 94
Abnormal Movements and Prognosis in Schizophrenia
YARDEN, P. E., & DISCIPIO, W. J. (1971) · American Journal of Psychiatry · doi:10.1176/ajp.128.3.317 · Cited by 87 · cited 1×
“Motor disturbances including "Schnauzkrampf", stereotyped behavior, dyskinesia and choreiform movements (Yarden and Discipio, 1971) were often seen in schizophrenic patients (Stevens, 1977).”
Background
Research works printed but not linked: 2
- De Armond, S. J., Fusco, H. M., Dewey, M. M.: Structure of Human Brain. London: Oxford Univ. Press. 1974.
- Stevens, J.: Striatal function and schizophrenics. In: Psychobiology of the Striaturri (Cools, A. R., Lohman, A. H. M., van den Bercken, J. H. L., eds.), pp. 173?194. Amsterdam: Elsevier. 1977.
Cited by
ROBINSON, T., & BECKER, J. (1986) · Brain Research · doi:10.1016/s0006-8993(86)80193-7 · Cited by 2,106
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Robinson, T. E., & Becker, J. B. (1986) · Brain Research Reviews · doi:10.1016/0165-0173(86)90002-0 · Cited by 1,796
Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome
Paşca, S. P., Portmann, T., Voineagu, I., Yazawa, M., Shcheglovitov, A., Paşca, A. M., Cord, B., Palmer, T. D., Chikahisa, S., Nishino, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2576 · Cited by 585
“and postmortem studies of individuals with schizophreni”
Emerging principles of altered neural circuitry in schizophrenia
Benes, F. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00041-7 · Cited by 513
Winter, C., Djodari-Irani, A., Sohr, R., Morgenstern, R., Feldon, J., Juckel, G., & Meyer, U. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009206 · Cited by 242
“For example, there is biochemical evidence for enhanced HVA in the basal ganglia of schizophrenia patients (Toru et al., 1982, 1988).”
Background(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1724 · Cited by 194
Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia
Nishikawa, T., Takashima, M., & Toru, M. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90046-0 · Cited by 196
Self-citationToru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio, H., Ichikawa, H., Kurumaji, A., Takashima, M., Mataga, N., et al. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06312.x · Cited by 191
Self-citationNeural basis of psychosis-related behaviour in the infection model of schizophrenia
Meyer, U., & Feldon, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.022 · Cited by 158
Ichinose, H., Ohye, T., Fujita, K., Pantucek, F., Lange, K., Riederer, P., & Nagatsu, T. (1994) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02250926 · Cited by 107
Meyer, U., & Feldon, J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1504-9 · Cited by 119
“For example, there is biochemical evidence of enhanced levels of DA and its metabolites DOPAC and HVA in dorsal and ventral striatal regions (e.g., Mackay et al. 1982; Toru et al. 1982, 1988).”
BackgroundResultMueller, H. T., Haroutunian, V. H., Davis, K. L., & Meador‐Woodruff, J. H. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.11.004 · Cited by 102
Cortical cholinergic markers in schizophrenia
Haroutunian, V. H., Davidson, M., Kanof, P. D., Perl, D. P., Powchik, P., LOSONCZY, M. F., McCrystal, J., Purohit, D. P., Bierer, L. M., & Davis, K. L. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90071-x · Cited by 67
Stachowiak, M. K., Kucinski, A. J., Curl, R., Syposs, C., Yang, Y., Narla, S. T., Terranova, C. J., Prokop, D., Klejbor, I., Bencherif, M., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.11.004 · Cited by 58
Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics
Watanabe, S., Nishikawa, T., Takashima, M., & Toru, M. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90290-4 · Cited by 53
Self-citationPantazopoulos, H., Stone, D., Walsh, J., & Benes, F. M. (2004) · Synapse · doi:10.1002/syn.20076 · Cited by 48
“…of the dopamine system in schizophrenia and bipolar disorder have reported increases in dopamine levels in the striatum and other cortical areas primarily due to neuroleptic treatment (Toru et al., 1982; Waddington et al., 1983; Lewis et al., 1987; Joyce et al., 1988; Kornhuber et al., 1989).”
BackgroundBenzodiazepine receptors increase in post-mortem brain of chronic schizophrenics
Kiuchi, Y., Kobayashi, T., Takeuchi, J., Shimizu, H., Ogata, H., & Toru, M. (1989) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf01759578 · Cited by 47
Self-citationEvidence for Reduced and Dysregulated Turnover of Dopamine in Schizophrenia
HERITCH, A. J. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.605 · Cited by 46
Dean, B. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2000.00747.x · Cited by 48
Decreased DOPAC in the anterior cingulate cortex of individuals with schizophrenia
Wyatt, R. J., Karoum, F., & Casanova, M. F. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00236-v · Cited by 38
McCollum, L. A., & Roberts, R. C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.041 · Cited by 31
“Previous studies in postmortem NAcc report conflicting results, typically finding no change (Crow et al., 1979; Farley et al., 1977; Owen et al., 1978; Toru et al., 1982) or increases (Bird et al.”
ResultInfluentialGenetic determination of mesencephalic tyrosine hydroxylase activity in the mouse
Vadász, C., Sziráki, I., Murthy, L. R., Vadász, I., Badalamenti, A. F., Kóbor, G., & Lajtha, Á. (1987) · Journal of Neurogenetics · doi:10.3109/01677068709102344 · Cited by 23
Klejbor, I., Kucinski, A. J., Wersinger, S. R., Corso, T. D., Spodnik, J. H., Dziewíatkowski, J., Moryś, J., Hesse, R. A., Rice, K. C., Miletich, R. S., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.06.006 · Cited by 21
“Thesefindings are consistentwithhumanPET studies (Meyer-Lindenberg et al., 2002) and postmortem evidence of increased subcortical DA synthesis in schizophrenia (Toru et al., 1982; Mueller et al., 2004).”
Afia, A. B., Vila, È., MacDowell, K. S., Ormazábal, A., Leza, J. C., Haro, J. M., Artuch, R., Ramos, B., & García‐Bueno, B. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02260-6 · Cited by 23
Neuropharmacology: Pathophysiology of schizophrenia — causal role for dopamine or noradrenaline?
Iversen, L. L., Reynolds, G. P., & Snyder, S. H. (1983) · Nature · doi:10.1038/305577a0 · Cited by 18
Wijnen, J. P., Haarsma, J., Boer, V. O., Luijten, P. R., der Stigchel, S. V., Neggers, S. F. W., & Klomp, D. W. J. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3278 · Cited by 16
“σ(2) 1⁄4 σ(2)between þ σ(2)within þ σ(2)random; [4]”
Genetic determination of mesencephalic tyrosine hydroxylase activity in the mouse
Vadász, C., Sziráki, I., Murthy, L. R., Vadász, I., Badalamenti, A. F., Kóbor, G., & Lajtha, Á. (1987) · Journal of Neurogenetics · doi:10.3109/01677068709167184 · Cited by 12
Postmortem Neurochemistry in Schizophrenia
Bracha, H. S., & Kleinman, J. E. (1986) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30639-7 · Cited by 12
Tyrosine hydroxylase localization in the nucleus accumbens in schizophrenia
McCollum, L. A., McCullumsmith, R. E., & Roberts, R. C. (2016) · Brain Structure and Function · doi:10.1007/s00429-015-1174-9 · Cited by 12
“NAcc are consistent with our findings (Farley et al. 1977; Owen et al. 1978; Crow et al. 1979; Toru et al. 1982).”
ResultThe Dopamine Hypothesis and Neurophysiology Concepts in Schizophrenia
HERITCH, A. J. (1992) · Reviews in the Neurosciences · doi:10.1515/revneuro.1992.3.3.207 · Cited by 6
(2014) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000271 · Cited by 5
“Catecholamines (CA) are candidate neurotransmitters, being involved in emotion, behavior, and the pathogenesis of psychoses [4].”
BackgroundD-Neuron: Is it Ligand-Producing Neuron of Taar1? From Schizophrenia Research
Ikemoto, K. (2013) · Journal of Community Medicine & Health Education · doi:10.4172/2161-0711.1000221 · Cited by 4
“DA dysfunction hypothesis suggested that mesolimbic DA hyperactivity caused positive symptoms such as paranoid-hallucinatory state of schizophrenia [1,2].”
BackgroundInfluentialD-Cell Hypothesis: Pathogenesis of Mesolimbic Dopamine Hyperactivity of Schizophrenia
Ikemoto, K. (2012) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2012.23048 · Cited by 4
“Mesolimbic DA hyperactivity [1,2], though frequently mentioned, the molecular basis of which has not yet been clarified.”
BackgroundInfluentialIkemoto, K. (2012) · Medicinal Chemistry · doi:10.4172/2161-0444.1000111 · Cited by 4
“DA dysfunction hypothesis suggested that mesolimbic DA hyperactivity caused positive symptoms such as paranoid-hallucinatory state of schizophrenia [1,2].”
BackgroundInfluentialNeurochemical studies of schizophrenia in Japan
Otsuki, S., & Akiyama, K. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02598.x · Cited by 4
Ikemoto, K. (2012) · Stem Cell Discovery · doi:10.4236/scd.2012.22009 · Cited by 3
“Nevertheless, molecular mechanism of mesolimbic DA hyperactivity [1,2] as DA dysfunction has not yet been well known.”
BackgroundMaio, A. D., Bassareo, V., Simone, G. D., HASSAN, A., Bertolino, A., Errico, F., Rampino, A., de Bartolomeis, A., & Usiello, A. (2026) · Schizophrenia · doi:10.1038/s41537-025-00722-x · Cited by 2
“For example, a previous study reported that patients receiving APs exhibit higher tyrosine hydroxylase activity 90 , suggesting enhanced dopamine synthesis and turnover.”
Involvement of So-Called D-Neuron (Trace Amine Neuron) in the Pathogenesis of Schizophrenia
Ikemoto, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803603-7.00020-3 · Cited by 2
Malik, T., & Haleem, D. J. (2012) · Journal of Food and Drug Analysis · doi:10.6227/jfda.2012200411 · Cited by 2
D-neuron in Schizophrenia Research
Ikemoto, K. (2013) · Advances in Biosensors and Bioelectronics · Cited by 2
“D-cell hypothesis” of schizophrenia: possible theory for mesolimbic dopamine hyperactivity
Ikemoto, K. (2012) · World Journal of Neuroscience · doi:10.4236/wjns.2012.23021 · Cited by 2
“DA dysfunction hypothesis suggests that mesolimbic DA hyperactivity causes positive symptoms such as paranoid-hallucinatory state of schizophrenia [1,2].”
BackgroundInfluentialA study of monoamine neuronal systems of schizophrenic patients: Using forensic autopsy brains
Ikemoto, K., Nishi, K., Kunii, Y., Wada, A., Yang, Q., Takase, I., Nishimura, A., & Niwa, S. (2009) · Legal Medicine · doi:10.1016/j.legalmed.2009.02.010 · Cited by 1
“Dopamine (DA) dysfunction is a hypothesis of schizophrenia [3], which has been widely accepted for explaining its etiology as well as glutamate dysfunction [4] and developmental deficits [5].”
BackgroundWhy D-neuron? Direction from Psychiatric Research
Ikemoto, K. (2013) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.s11-002 · Cited by 1
“DA dysfunction hypothesis suggests that mesolimbic DA hyperactivity causes positive symptoms such as paranoid-hallucinatory state of schizophrenia [1,2].”
BackgroundInfluentialBolton, M. M. (2013) · Digital Scholarship - UNLV (University of Nevada Reno) · doi:10.34917/4797986
Why D-neuron? Importance in schizophrenia research
Ikemoto, K. (2012) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2012.224055
“Dopamine (DA) dysfunction [1,2], glutamate dysfunction [3,4], neurodevelopmental deficits [5,6], or neural stem cell (NSC) dysfunction [7,8] are well-known hypotheses for etiology of schizophrenia.”
BackgroundInfluentialIkemoto, K., Oda, T., Nishimura, A., & Nishi, K. (2011) · Case Reports in Neurological Medicine · doi:10.1155/2011/381059
Ikemoto, K. (2015) · Pharmacovigilance and Pharmacoepidemiology · doi:10.33805/2638-8235.102
Hornykiewicz, O. (1983) · Nature · doi:10.1038/305577b0
Extrastriatal dopamine D2/3 receptors in schizophrenia
Tuppurainen, H. (2011) · UEF eRepo (University of Eastern Finland)
The Schizophrenia hypothesis: Tyrosine hydroxylase pathway
Özdemir, O. (2025) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1574857
Afia, A. B., Vila, È., MacDowell, K. S., Ormazabal, A., Leza, J. C., Haro, J. M., Artuch, R., Ramos, B., & Garcia-Bueno, B. (2021) · Figshare · doi:10.6084/m9.figshare.16608941
Walpole, S. J., Lum, J. S., Chesworth, R., Walker, A. K., Karl, T., Weickert, C. S., & Newell, K. A. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.06.020
Metadata
- Authors
- Toru, M., Nishikawa, T., Mataga, N., & Takashima, M.
- Venue
- Journal of Neural Transmission
- Published
- 1982-09
- Volume
- 54
- Issue
- 3-4
- Pages
- 181-191
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2033542637
- Cited by
- 57
- References
- 22
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 1 · 2021: 3 · 2020: 1 · 2016: 3 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 8
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- schizophrenia, dopamine metabolism, basal ganglia, homovanillic acid, tyrosine hydroxylase, putamen, caudate nucleus, nucleus accumbens, dopamine turnover, catatonic schizophrenia, dopaminergic terminals, postmortem brain
- MeSH terms
- Adult, Basal Ganglia, Brain, Brain Chemistry, Dopamine, Female, Humans, Male, Middle Aged, Postmortem Changes, Schizophrenia, Tyrosine 3-Monooxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.